1Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM- 2004 study [ J ]. Haematologica,2006,91 ( 8 ) : 1068 - 1075.
3Yamazaki T, Kume H, Murase S, et al. Epidemiology of visceral mycoses : analysis of data in annual of the pathological autopsy cases in Japan [ J]. J Clin Microbiol, 1999,37 (6) :1732 - 1738.
4Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasire fungal infections in immunocompromised patients with cancer and hematopoietie stem cell transplants : an international consensus [ J]. Clin Infect Dis,2002,34:7 - 14.
5Jarque I, Andreu R ,Salavert M, et al. Value of Aspergillus galactomannan antigen detection in the diagnosis and follow-up of invasive aspergillosis in hematological patients [ J ]. Rev Iberoam Micol,2003,20( 3 ) : 116 - 118.
6Moragues MD, Amutio E, Garcia-Ruiz JC, et al. Usefulness of galactomannan detection in the diagnosis and follow-up of hematological patients with invasive aspergillosis [ J]. Rev Iberoam Micol, 2003,20(3) :103 -110.
7Ulusakarya A, Chachaty E, Vantelon JM, et al. Surveillance of Aspergillus galactomannan antigenemia for invasive aspergillosis by enzyme-linked immunosorbent assay in neutropenic patients treated for hematological malignancies [ J ]. Hematol J, 2000, 1 ( 2 ) : 111 - 116.
8Rimek D, Redetzke K, Steiner B, et al. Experience with the Platelia Candida ELISA for the diagnosis of invasive candidosis in neutropenic patients [J]. Mycoses,2004,47:27 -31.
9Pazos C, del Palacio A. Early diagnosis of invasive aspergillosis in neutropenic patients with bi-weekly serial screening of circulating galactomannan by Platelia Aspergillus [ J ]. Rev Iberoam Micol, 2003,20 ( 3 ) :99 - 102.
10Walsh TJ, Shoham S, Petraitiene R, et al. Detection of galactomannan antigenemia in patients receiving piperacillin-tazobactam and correlations between in vitro, in vivo, and clinical properties of the drag-antigen interaction [ J ]. J Clin Microbiol, 2004,42 (10) :4744 -4748.
2Jarvis WR . Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis, 1995,20:1526-1530.
3Kao AS, Brandt ME, Pruitt WR, et al. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis, 1999,29:1164-1170.
4Verduyn Lunel FM, Meis JF, Voss A, et al. Nosocomial fungal infections:candidemia. Diagn Microbiol Infect Dis, 1999,34:213-220.
5Edmond MB, Wallace SE, McClish DK,et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis, 1999,29: 239-244.
6Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990.National Nosocomail Infections Surveillance System . J Infect Dis, 1993, 167:1247-1251.
7Haddad NE, Powderly WG. The changing face of mycoses in patients with HIV/AIDS. AIDS Read, 2001,11: 375-378.
8Rex JH, Bennett JE, Sugar AM, et al. Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Clin Infect Dis, 1995,21:994-996.
9Pfalller MA, Messer SA, Hollis RJ, et al. Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. Diagn Microbiol Infect Dis, 1999,33:217-222.
10Abbas J, Bodey GP, Hanna HA, et al. Candida krusei fungemia. An escalating serious infection in immunocompromised patients. Arch Intern Med , 2000,160: 2659-2664.
